Eric Messamore

Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. In a Phase 3 clinical ...

John Edwards , MD, MBA;

Eric Messamore ;

01/19/2023

Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-label Extension Study

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. A recent Phase 3 trial...

Ian D'Souza , PhD;

Eric Messamore ;

01/19/2023

Lumateperone 42 mg in an Open-Label Switch Study in Patients With Stable Schizophrenia: Results by Previous Antipsychotic

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. This analysis of open-...

Tobie Escher , PhD;

Eric Messamore ;

01/19/2023

Lumateperone in Pooled Late-Phase Schizophrenia Trials: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder as monotherapy and as a...

Leslie Citrome , MD;

Eric Messamore ;

01/19/2023